GBG beim ESMO 2026 in Madrid

GBG-Beteiligung auf dem ESMO 2026 in Madrid

Auch in diesem Jahr ist die GBG an der Präsentation neuer wissenschaftlicher Erkenntnisse beteiligt. 

Poster Präsentation “Stereotactic Radiosurgery (SRS) and Radiotherapy in Breast Cancer Brain Metastases (BCBM): Subtype-Specific Analysis of the BMBC Registry” präsentiert von Raphael Bodensohn

Präsentation: 24.10.2026 um 12:00 - 12:45 Uhr in der Poster Area - Hall 5

Weitere Beiträge mit GBG-Beteiligung 

• Educational Session: Educational session: Optimising treatment for HER2+ early breast cancer

What to do after optimal neoadjuvant therapy?

Präsentierende Autorin: Sibylle Loibl

Präsentation: 25.10.2026 11:15 - 11:35 Barcelona Auditorium - Hall 9

• DESTINY-Breast09

DB-09 - A DESTINY-Breast (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs) (LBA49)

Präsentierende Autorin: Cristina Saura Manich

Präsentation: 26.10.2026 10:15 - 11:45 Alicante Auditorium - Hall 6

• DESTINY-Breast05

Patient-Reported Outcomes (PROs) From DESTINY-Breast05: Health-Related Quality of Life (HRQoL) With Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients (Pts) With High-Risk HER2-Positive Early Breast Cancer (eBC) (538RO)

Präsentierender Autor: Gustavo Werutsky

Präsentation:  23.10.2026 16:15 - 17:45 Alicante Auditorium - Hall 6

• PANTHER

Independent validation of an AI-based prognostic assay in clinically high-risk ER+/HER2- early breast cancer: Results from the phase III PANTHER trial (551P)

Präsentierender Autor: Ioannis Zerdes

Präsentation: 24.10.2026 12:00 - 12:45 Poster Area - Hall 5

Weitere Beiträge unserer Subboard-Mitglieder

• Vesna Bjelic-Radisic

Rapid oral 1 and invited discussant: Breast cancer, advanced stage 

Präsentation: 24.10.2026 11:09 - 11:21 Almeria Auditorium - Hall 9

•  Thomas Decker

Poster: advanced breast cancer, other

Clinical characteristics and outcomes of endocrine-resistant hormone receptor positive, HER2-negative (HR+/HER2−) advanced breast cancer: Insights from the AGO-B CAPTOR trial (16P)

Präsentation: 24.10.2026 12:00 - 12:45 Poster Area-Hall 5

• Carsten Denkert

Special symposium: Incorporation of biomarkers for early breast cancer 

Dynamic tissue-based biomarkers to guide treatment

Präsentation: 26.10.2026 14:45 - 15:05 Almeria Auditorium - Hall 9

• Peter A. Fasching

1. Industry satellite symposium: Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC

Präsentation: 25.10.2026 13:00 - 14:30 Malaga Auditorium - Hall 3

2. Industry satellite symposium: Novartis - From Risk to Recurrence: Personalizing CDK4/6 Inhibitor Strategies in HR+/HER2− Breast Cancer

Präsentation: 26.10.2026 13:00 - 14:30 Madrid Auditorium - Hall 4

3. Poster: Breast cancer, earyl stage

Health-related quality of life (HRQoL) in patients (pts) with HR+/HER2− early breast cancer (EBC) receiving adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone: 5-y NATALEE subgroup analyses by nodal status and stage (581P)

Präsentation: 24.10.2026 12:00 - 12:45 Poster Area - Hall 5

4. Proffered paper 2: Breast cancer, early and advanced stage

Präsentation: 24.10.26 09:00 - 09:10 Alicante Auditorium - Hall 6

• Athina Kostara

Poster: Supportive care

Scalp cooling meaningfully reduces chemotherapy-induced alopecia (CIA): Real-world evidence from a 500-breast cancer patient cohort (3995P)

Präsentation: 24.10.2026 12:00 - 12:45 Poster Area - Hall 5

• Frederik Marmé

1 Educational session: Update on the mangement of endometrial cancer in the era of molecular classification

Current evidence and development of ADCs in EC

Präsentation: 23.10.2026 14:10 - 14:30 Murcia Auditorium - Hall 3

2. Industry satellite symposium: AbbVie - Riding the Wave of Innovation Towards Personalized Medicine in Ovarian Cancer

New ADC Horizons: Sequencing Strategies, Emerging Therapies, and the Next Frontier in
Ovarian Cancer

Präsentation: 23.10.2026 10:25 - 10:50 Leon Auditorium - Hall 4

3. Poster: Gynaecological cancers

AGO OVAR 27, a non-randomised phase II window-of-opportunity (WoO) trial of olaparib (Ola) alone (cohort A) or in combination with durvalumab (cohort B) prior to primary debulking surgery (PDS) in high-grade ovarian cancer (OC): Primary results of cohort (1267P)

Präsentation: 26.10.2026 12:00 - 12:45 Poster Area - Hall 5

• Volkmar Müller

Industry satellite symposium: Pfizer Oncology - Metastatic Breast Cancer: Individualised Decision-Making in Focus

Präsentation: 25.10.2026 18:30 - 20:00 Madrid Auditorium - Hall 4

• Marc Thill

Poster: HR+ breast cancer

Optimal treatment strategies following first-line CDK4/6 inhibitor in HR+ HER2- metastatic breast cancer: Real-world evidence from the OPAL registry platform (1876P)

Präsentation: 24.10.2026 12:00 - 12:45 Poster Area - Hall 5